A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 May 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis
- Focus Adverse reactions
- 01 May 2017 Planned End Date changed from 1 May 2020 to 1 Oct 2020.
- 01 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
- 17 Mar 2017 New trial record